Results 11 to 20 of about 1,866 (169)

Bimekizumab Pain Outcomes in Patients with Hidradenitis Suppurativa: Pooled 48-Week Results from BE HEARD I&II Phase 3 Randomized Clinical Trials [PDF]

Pain and Therapy
Introduction Pain is a debilitating symptom of hidradenitis suppurativa (HS). Bimekizumab, a humanized IgG1 monoclonal antibody, selectively inhibits IL-17A and IL-17F.
John R. Ingram, Hideki Fujita, Alice B. Gottlieb, Hadar Lev-Tov, Errol Prens, Christopher J. Sayed, Vivian Y. Shi, Jacek C. Szepietowski, Kenzo Takahashi, John W. Frew, Jérémy Lambert, Leah Davis, Tae Oh, Robert Rolleri, Marie-Hélène Saintmard, Lauren A. V. Orenstein   +15 more
doaj   +3 more sources

Indirect Comparison Between Bimekizumab and Brodalumab for the Management of Moderate to Severe Psoriasis: A 36-Week Real-Life Study

Dermatology and Therapy
Introduction Bimekizumab and brodalumab are characterized by a different mechanism of action if compared to the other anti-interleukin (IL)-17s which target IL-17A.
Luca Potestio, Fabrizio Martora, Flavia Raia, Gioacchino Lucagnano, Claudio Brescia, Ginevra Torta, Matteo Megna   +6 more
doaj   +3 more sources

Bimekizumab as-needed dosing in patients with psoriasis: a case series [PDF]

Journal of Dermatological Treatment
Introduction Despite significant advances in psoriasis treatment, off-label dosing studies of psoriasis biologic therapies are limited.Materials and methods In this retrospective case series, medical records from 28 patients with moderate-to-severe ...
Carlota Abbad-Jaime De Aragón, Emilio Berna-Rico, Pedro Jaén, Andrew Blauvelt, Álvaro González-Cantero   +4 more
doaj   +3 more sources

Severe Paradoxical Scalp Psoriasis Induced by Bimekizumab in a Young Multifailure Hidradenitis Suppurativa Patient

Dermatology and Therapy
This article explores the ongoing research into the complex pathogenesis of hidradenitis suppurativa (HS) and the persistent challenges in finding effective treatments. With 113 clinical studies currently listed on ClinicalTrials.gov, the quest for novel
Fabrizio Martora, Teresa Battista, Luca Potestio, Matteo Megna   +3 more
doaj   +3 more sources

Bimekizumab

Current Dermatology Reports, 2020
Purpose of Review: Bimekizumab, a novel monoclonal antibody directed against both interleukin (IL)-17A and IL-17F, is in clinical development as a treatment for psoriasis and psoriatic arthritis. The purpose of this review is to highlight the roles of IL-17A and IL-17F in psoriatic inflammation as well as the clinical data on bimekizumab that has been ...
Blauvelt A., Chiricozzi A., Ehst B. D.
openaire   +2 more sources

Real-World Experience of Bimekizumab in a Cohort of 109 Patients Over 48 Weeks and Identification of Predictive Factors for an Early Super Response and Risk of Adverse Events [PDF]

Psoriasis
Introduction Psoriasis is a chronic inflammatory skin disease significantly impairing quality of life. The introduction of biologic therapies, such as bimekizumab—a monoclonal antibody targeting IL-17A and IL-17F—has revolutionized treatment outcomes ...
Z. Fratton, S. Bighetti, L. Bettolini, V. Maione, M. Arisi, C. Buligan, G. Stinco, E. Errichetti   +7 more
semanticscholar   +2 more sources

Bimekizumab provided rapid improvements in patient-reported symptoms and health-related quality of life in patients with active psoriatic arthritis: pooled 16-week results from two phase 3 studies

RMD Open
Objectives To assess impact of bimekizumab treatment on patient-reported outcomes and health-related quality of life (HRQoL) in patients with active psoriatic arthritis (PsA), using 16-week data from two phase 3 studies.Methods BE OPTIMAL (NCT03895203 ...
Joseph F Merola, Philip J Mease, Dafna D Gladman, M Elaine Husni, Nadine Goldammer, Jason Coarse, William Tillett, Vanessa Taieb, Jeremy Lambert, Barbara Ink   +9 more
doaj   +2 more sources

Bimekizumab for the treatment of psoriatic arthritis

Expert Review of Clinical Immunology, 2023
Interleukin (IL)-17A and IL-17F have overlapping roles in pro-inflammatory signaling and have been implicated in the pathogenesis of psoriatic disease. Bimekizumab is the first human monoclonal antibody to selectively inhibit IL-17F in addition to IL-17A.
Yoshiya Tanaka, Stevan Shaw
openaire   +3 more sources

Effect of Bimekizumab on Patient-Reported Outcomes and Work Productivity in Patients With Psoriatic Arthritis: 1-Year Results From 2 Phase III Studies [PDF]

Journal of Rheumatology
Objective To assess the longer-term effect of bimekizumab up to 1 year on patient-reported symptoms, health-related quality of life (HRQOL), and work productivity in patients with active PsA who were biologic disease-modifying antirheumatic drug (bDMARD)-
D. Gladman, P. Mease, L. Gossec, M. Husni, A. Gottlieb, B. Ink, R. Bajracharya, J. Coarse, Nikos Lyris, Jérémy Lambert, W. Tillett   +10 more
semanticscholar   +2 more sources

Bimekizumab for the treatment of psoriatic disease

Expert Opinion on Biological Therapy, 2018
Psoriasis and psoriatic arthritis are common diseases with significant physical and emotional burden. Several biologics are FDA-approved to treat psoriasis and psoriatic arthritis, though some patients remain refractory to, or have lost response to, therapy and/or cannot tolerate the associated risks and side effects. Bimekizumab is a new biologic that
Nicola E, Natsis, Alice B, Gottlieb
openaire   +3 more sources